基于AI机器学习技术构建外科术后临床结局预测模型和个性化营养策略的研究

注册号:

Registration number:

ChiCTR2500110693 

最近更新日期:

Date of Last Refreshed on:

2025-10-17 17:28:44 

注册时间:

Date of Registration:

2025-10-17 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于AI机器学习技术构建外科术后临床结局预测模型和个性化营养策略的研究

Public title:

An AI Machine Learning Model for Predicting Postoperative Clinical Outcomes and Guiding Personalized Nutritional Strategies

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于AI机器学习技术构建外科术后临床结局预测模型和个性化营养策略的研究

Scientific title:

An AI Machine Learning Model for Predicting Postoperative Clinical Outcomes and Guiding Personalized Nutritional Strategies

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王晨 

研究负责人:

郑璇 

Applicant:

Wang Chen 

Study leader:

Zheng Xuan 

申请注册联系人电话:

Applicant telephone:

+86 183 0195 3893

研究负责人电话:

Study leader's
telephone:

+86 159 2181 1369

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

284329225@qq.com

研究负责人电子邮件:

Study leader's E-mail:

15921811369@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市杨浦区长海路168号长海医院

研究负责人通讯地址:

上海市杨浦区长海路168号长海医院

Applicant address:

168 Changhai Road, Yangpu District, Shanghai

Study leader's address:

168 Changhai Road, Yangpu District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海长海医院

Applicant's institution:

Shanghai Changhai Hospital

研究负责人所在单位:

上海长海医院

Affiliation of the Leader:

Shanghai Changhai Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

CHEC2025-352

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海长海医院伦理委员会

Name of the ethic committee:

Shanghai Changhai Hospital Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

2025-09-10 00:00:00

伦理委员会联系人:

张优琴

Contact Name of the ethic committee:

Zhang Youqin

伦理委员会联系地址:

上海市杨浦区长海路168号

Contact Address of the ethic committee:

168 Changhai Road, Yangpu District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 139 1835 5518

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海长海医院

Primary sponsor:

Shanghai Changhai Hospital

研究实施负责(组长)单位地址:

上海市杨浦区长海路168号长海医院

Primary sponsor's address:

168 Changhai Road, Yangpu District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

长海医院

具体地址:

杨浦区长海路168号

Institution
hospital:

Shanghai Changhai Hospital

Address:

168 Changhai Road, Yangpu District

经费或物资来源:

自筹基金

Source(s) of funding:

Self-funded

研究疾病:

外科手术  

Target disease:

Surgical procedures

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

拟通过 AI 机器学习构建外科术后临床结局预测模型,探索术后个性化营养策略,为改善外科患者预后、创新营养干预模式提供依据。  

Objectives of Study:

To develop an AI machine learning-based predictive model for postoperative clinical outcomes and to explore personalized nutritional strategies, thereby providing evidence for improving patient prognosis and innovating nutritional intervention paradigms

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.合并难以控制的代谢性疾病; 2.手术未达到预期治疗目标; 3.处于妊娠或哺乳期的女性患者; 4.合并严重脏器功能障碍; 5.临床资料严重缺失或关键指标无法获取者。

Exclusion criteria:

1. Poorly controlled metabolic diseases. 2. Surgical procedures that did not accomplish their predefined therapeutic goals. 3. Female patients who were pregnant or breastfeeding. 4. Coexisting severe impairment of major organ function. 5. Significant gaps in clinical documentation or unavailability of key data that compromised outcome assessment.

研究实施时间:

Study execute time:

From 2025-09-01 00:00:00 To 2028-07-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-10-31 00:00:00 To 2025-12-31 00:00:00

干预措施:

Interventions:

组别:

Case series

样本量:

4859

Group:

Case series

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海市 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海长海医院 

单位级别:

三甲 

Institution
hospital:

Shanghai Changhai Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

白蛋白

指标类型:

主要指标

Outcome:

albumin

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总蛋白

指标类型:

主要指标

Outcome:

total protein

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

前白蛋白

指标类型:

主要指标

Outcome:

prealbumin

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

转铁蛋白

指标类型:

主要指标

Outcome:

transferrin

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

视黄醇结合蛋白

指标类型:

主要指标

Outcome:

retinol conjugated protein

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C反应蛋白

指标类型:

主要指标

Outcome:

CRP

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

降钙素原

指标类型:

主要指标

Outcome:

PCT

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

身高

指标类型:

主要指标

Outcome:

height

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

体重

指标类型:

主要指标

Outcome:

weight

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血常规:白细胞计数;中性粒细胞;淋巴细胞计数;红细胞计数;血小板计数;血红蛋白;红细胞分布宽度

指标类型:

次要指标

Outcome:

Blood routine test: WBC; NEUT; LYM; RBC; PLT; Hb; RDW

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝功能:间接胆红素;直接胆红素;总胆红素;总胆汁酸;丙氨酸氨基转移酶;门冬氨酸氨基转移酶;碱性磷酸酶;乳酸脱氢酶;γ-谷氨酰转移酶;AST线粒体同工酶

指标类型:

次要指标

Outcome:

Liver function: IBIL; DBIL; TBIL; TBA; ALT; AST; ALP; LDH; GGT; mAST

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肾功能:肌酐;尿素;尿酸;肾小球滤过率估算值

指标类型:

次要指标

Outcome:

Renal function: Cr; Urea; UA; eGFR

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

凝血功能:凝血酶原活动度;血浆D-二聚体;凝血酶原时间;凝血酶原时间对照;凝血酶原时间国际标准化比值;纤维蛋白降解产物;纤维蛋白原;活化部分凝血活酶时间;凝血酶时间

指标类型:

次要指标

Outcome:

Coagulation function: PTA; D-Dimer; PT; PT-control; INR; FDP; FIB; APTT; TT

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 90 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国临床实验注册中心

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

China Clinical Laboratory Registration Center

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例报告表(CRF)一式三份(无碳复写)由研究者和研究医生填写,入选病例必须完成CRF。完成的CRF由临床监查员确认后收集,第一联移交数据管理员进行数据录入与管理工作。第一联移交后,CRF的内容不再做任何修改。CRF的每一页都必须标明受试者的研究病例编号,该编号由4位数字的受试者编号、4位数字的受试者姓名缩写和4位数字的随机号。CRF将由研究者妥善保管在上锁的文件柜中,只有试验相关研究人员可查阅。所有受试者电子版资料将录入需要密码登录的安全的数据库中,只有实验相关人员可登录。所有试验相关数据在试验完成后至少保留五年。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The Case Report Form (CRF) is completed in triplicate (carbonless copy) by the investigator and study physician, and the CRF must be completed for enrolled cases. completed CRFs are collected after confirmation by the clinical monitor, and the first link is transferred to the data manager for data entry and management. Each page of the CRF must be labeled with the subject's study case number, which consists of a 4-digit subject code, a 4-digit abbreviation of the subject's name, and a 4-digit random code. The CRF will be kept in a locked file cabinet by the investigator and will be accessible only to the study staff involved in the trial. All subject data will be entered electronically into a secure database requiring password access and will be accessible only by trial-related personnel. All trial-related data will be retained for at least five years after completion of the trial.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2025-10-17 17:28:26